Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.98)
# 1,298
Out of 5,182 analysts
10
Total ratings
85.71%
Success rate
53.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Buy | $14 | $7.21 | +94.17% | 1 | Mar 2, 2026 | |
| EXEL Exelixis | Upgrades: Outperform | $48 | $44.94 | +6.81% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $22.41 | -10.75% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $3.69 | +143.90% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.52 | +296.83% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $15.13 | +18.97% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $30.73 | -12.14% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $104.50 | -59.81% | 1 | Aug 8, 2023 |
Relmada Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $14
Current: $7.21
Upside: +94.17%
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $44.94
Upside: +6.81%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $22.41
Upside: -10.75%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $3.69
Upside: +143.90%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.52
Upside: +296.83%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $15.13
Upside: +18.97%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $30.73
Upside: -12.14%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $104.50
Upside: -59.81%